William Harnisch’s Acadia Pharmaceuticals ACAD Stock Holding History

William Harnisch’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,000	Closed	-$45K	–	50
2018 Q1	$45K	Buy	+2,000	New	+$55.4K	0.01%	38

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

William Harnisch's ACAD Position: Q2 2018 in Review

William Harnisch sold out of Acadia Pharmaceuticals (ACAD) in Q2 2018, closing a stake of 2,000 shares — an estimated $45K sold.

William Harnisch first reported a position in ACAD in Q1 2018 and held it in 1 quarter. The position peaked at $45K in Q1 2018. 187 funds tracked by Wall St. Rank hold ACAD as of Q2 2018.

William Harnisch reported no remaining Acadia Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
William Harnisch sold 2,000 Acadia Pharmaceuticals shares in Q2 2018, an estimated $45K.
William Harnisch first reported a position in Acadia Pharmaceuticals in Q1 2018 and held it in 1 quarter.
William Harnisch's Acadia Pharmaceuticals position peaked at $45K in Q1 2018.
187 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2018.

Based on Peconic Partners's 13F filing for Q2 2018, filed 14 Aug 2018.